Bio-Gene Expands Asian Mosquito Trials and Secures US Patent to 2040

Asian Expansion Targets Mosquito-Borne Disease Vectors

Bio-Gene Technology (ASX:BGT) has significantly broadened its mosquito vector control program by initiating evaluations of its Flavocide and Qcide insecticides against mosquito species prevalent in Asia. The focus is on Aedes aegypti, Aedes albopictus, and Culex quinquefasciatus, vectors responsible for spreading dengue, chikungunya, and Zika viruses. Testing, aligned with World Health Organisation guidelines, is underway in Singapore and surrounding regions, with initial results anticipated by the end of calendar 2026.

This regional push addresses escalating insecticide resistance that undermines existing control products. Flavocide and Qcide’s novel mode of action offers a fresh approach, potentially effective against resistant mosquito populations. Success here would not only validate these products’ efficacy but also inform their commercialisation strategy across Asia’s public health markets, where diseases like dengue impose a substantial ongoing health burden.

Regulatory and Commercial Progress on Multiple Fronts

Bio-Gene’s toxicology studies for Flavocide continue, with OECD 424 acute neurotoxicity and OECD 443 one-generation reproductive toxicity studies progressing. A preliminary report for the OECD 424 study is now expected in September 2026, delayed from May due to a software validation issue. These studies underpin Bio-Gene’s regulatory submission plans, critical for gaining approvals in Australia and beyond.

Meanwhile, the company is advancing its commercial ambitions in Japan through a partnership with Sumitomo Corporation and Nakashima Trading Co. Efforts during the quarter included drafting commercial terms, preparing import approval applications, and developing prototype formulations for Qcide, targeting a product launch in the late 2026 timeframe. This aligns with Bio-Gene’s strategy to penetrate household nuisance insect markets in Japan, leveraging local partners’ expertise.

US Patent Boosts Flavocide’s Intellectual Property Portfolio

A key milestone arrived with the United States Patent and Trademark Office granting allowance for a patent covering Flavocide’s active compound, flavesone, in synergistic combination with permethrin and pyrethrin. This patent, expected to be formally granted within months, extends Bio-Gene’s intellectual property protection in the US until 2040.

These synergistic combinations are designed to enhance insecticidal efficacy beyond what individual ingredients achieve alone, positioning Bio-Gene to develop differentiated pest control products. The patent strengthens the company’s global IP estate, complementing granted patents in Australia, Japan, New Zealand, and African jurisdictions, and supports potential licensing or co-development deals.

Capital Raising Fuels Development and Commercialisation

To underpin these activities, Bio-Gene completed a $3.275 million capital raising comprising a $2.775 million placement and a partially underwritten $500,000 Share Purchase Plan. The placement shares were issued at $0.025 each, with options attached subject to shareholder approval, exercisable at $0.035 and expiring in October 2027. Funds are earmarked for completing Flavocide safety studies, scaling Qcide production, product development, strategic projects, and working capital.

As of 30 June 2026, Bio-Gene held $1.94 million in cash, reflecting the recent capital influx. Operating cash outflows for the quarter were $636,000, consistent with ongoing R&D and commercialisation expenses. Payments to related parties, including executive and non-executive directors, amounted to $190,689.

Industry Recognition and Market Engagement

Adding to the quarter’s positives, Bio-Gene’s Executive Director of R&D, Peter May, received the Envu Australian Individual Excellence Professional Pest Management Award 2026. This accolade recognises his outstanding contribution to the Australian commercial pest management industry. May’s presence at the FAOPMA Pest Summit in New Zealand also facilitated engagement with key collaborators and suppliers in regional markets.

Investor relations activities included presentations at the Ignite Investment Summit in Singapore and a June webinar hosted by CEO Tim Grogan, providing updates on company progress and capital use plans.